Actelion wins European approval for pulmonary arterial hypertension drug
Tracleer is claimed to be the first pulmonary arterial hypertension (PAH) treatment ever to be investigated in a clinical study that exclusively enrolled patients with mildly symptomatic pulmonary
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.